| Active surveillance program for prostate cancer: an update of the Johns Hopkins experience JJ Tosoian, BJ Trock, P Landis, Z Feng, JI Epstein, AW Partin, PC Walsh, ... Journal of Clinical Oncology 29 (16), 2185-2190, 2011 | 696 | 2011 |
| Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer JJ Tosoian, M Mamawala, JI Epstein, P Landis, S Wolf, BJ Trock, ... Journal of Clinical Oncology 33 (30), 3379-3385, 2015 | 616 | 2015 |
| Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9 … AU Kishan, RR Cook, JP Ciezki, AE Ross, MM Pomerantz, PL Nguyen, ... Jama 319 (9), 896-905, 2018 | 312 | 2018 |
| Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations JJ Tosoian, MA Gorin, AE Ross, KJ Pienta, PT Tran, EM Schaeffer Nature Reviews Urology 14 (1), 15-25, 2017 | 279 | 2017 |
| Active surveillance for prostate cancer: current evidence and contemporary state of practice JJ Tosoian, HB Carter, A Lepor, S Loeb Nature Reviews Urology 13 (4), 205-215, 2016 | 250 | 2016 |
| Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort JJ Tosoian, M Mamawala, JI Epstein, P Landis, KJ Macura, ... European urology 77 (6), 675-682, 2020 | 184 | 2020 |
| Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program JJ Tosoian, S Loeb, A Kettermann, P Landis, DJ Elliot, JI Epstein, ... The Journal of urology 183 (2), 534-538, 2010 | 165 | 2010 |
| Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho, K Yousefi, P Hurley, ... Prostate cancer and prostatic diseases 20 (1), 28-35, 2017 | 145 | 2017 |
| Association of [− 2] proPSA with biopsy reclassification during active surveillance for prostate cancer JJ Tosoian, S Loeb, Z Feng, S Isharwal, P Landis, DJ Elliot, R Veltri, ... The Journal of urology 188 (4), 1131-1136, 2012 | 143 | 2012 |
| A systematic review of the evidence for the decipher genomic classifier in prostate cancer NK Jairath, A Dal Pra, R Vince Jr, RT Dess, WC Jackson, JJ Tosoian, ... European urology 79 (3), 374-383, 2021 | 136 | 2021 |
| Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy MR Chappidi, M Kates, HD Patel, JJ Tosoian, DR Kaye, NA Sopko, ... Urologic oncology: seminars and original investigations 34 (6), 256. e1-256. e6, 2016 | 122 | 2016 |
| PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer J Tosoian, S Loeb The Scientific World Journal 10 (1), 1919-1931, 2010 | 121 | 2010 |
| Prediction of pathological stage based on clinical stage, serum prostate‐specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era JJ Tosoian, M Chappidi, Z Feng, EB Humphreys, M Han, CP Pavlovich, ... BJU international 119 (5), 676-683, 2017 | 115 | 2017 |
| Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance JJ Tosoian, E JohnBull, BJ Trock, P Landis, JI Epstein, AW Partin, ... The Journal of urology 190 (4), 1218-1223, 2013 | 112 | 2013 |
| Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens PL Nguyen, Z Haddad, AE Ross, NE Martin, S Deheshi, LLC Lam, ... European urology 72 (5), 845-852, 2017 | 110 | 2017 |
| Prostate Health Index density improves detection of clinically significant prostate cancer JJ Tosoian, SC Druskin, D Andreas, P Mullane, M Chappidi, S Joo, ... BJU international 120 (6), 793-798, 2017 | 100 | 2017 |
| Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer SC Druskin, JJ Tosoian, A Young, S Collica, A Srivastava, K Ghabili, ... BJU international 121 (4), 619-626, 2018 | 94 | 2018 |
| Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer HB Kaur, LB Guedes, J Lu, L Maldonado, L Reitz, JR Barber, ... Modern Pathology 31 (10), 1539-1552, 2018 | 90 | 2018 |
| The role of multiparametric magnetic resonance imaging/ultrasound fusion biopsy in active surveillance TM Ma, JJ Tosoian, EM Schaeffer, P Landis, S Wolf, KJ Macura, JI Epstein, ... European urology 71 (2), 174-180, 2017 | 89 | 2017 |
| Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location FA Faisal, D Sundi, JJ Tosoian, V Choeurng, M Alshalalfa, AE Ross, ... European urology 70 (1), 14-17, 2016 | 89 | 2016 |
